60 Recruiting Acute Myeloid Leukemia Phase 1 Clinical Trials
Active phase 1 studies for acute myeloid leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Acute Myeloid Leukemia studiesPhase 1 Studies for Acute Myeloid Leukemia
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
📍 H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
📍 City of Hope National Medical Center /ID# 269273 — Duarte, California
View Study & Checklist ➔Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
📍 Loma Linda University Cancer Center — Loma Linda, California
View Study & Checklist ➔Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
📍 City of Hope — Duarte, California
View Study & Checklist ➔Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
📍 Los Angeles General Medical Center — Los Angeles, California
View Study & Checklist ➔Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
📍 Texas Children's Hospital — Houston, Texas
View Study & Checklist ➔A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
📍 Princess Margaret Centre Centre — Toronto, Ontario
View Study & Checklist ➔Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
📍 Johns Hopkins All Children's Hospital — St. Petersburg, Florida
View Study & Checklist ➔Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
📍 Greenebaum Cancer Center, University of Maryland Medical Systems — Baltimore, Maryland
View Study & Checklist ➔A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
📍 City of Hope — Duarte, California
View Study & Checklist ➔Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
📍 Northside Hospital, Inc. — Atlanta, Georgia
View Study & Checklist ➔Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
📍 UT MD Anderson — Houston, Texas
View Study & Checklist ➔Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View Study & Checklist ➔ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
📍 Mayo Clinic - Phoenix — Phoenix, Arizona
View Study & Checklist ➔Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
📍 Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM) — The Bronx, New York
View Study & Checklist ➔Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
📍 Texas Children's Cancer and Hematology Center — Houston, Texas
View Study & Checklist ➔Revumenib in Combination With 7+3 + Midostaurin in AML
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
📍 MD Anderson — Houston, Texas
View Study & Checklist ➔Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
📍 Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 University of Miami — Miami, Florida
View Study & Checklist ➔Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
📍 University of Virginia — Charlottesville, Virginia
View Study & Checklist ➔Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
📍 University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
View Study & Checklist ➔8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
📍 University of Iowa Health Care — Iowa City, Iowa
View Study & Checklist ➔Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔